trending Market Intelligence /marketintelligence/en/news-insights/trending/oijaYM9bnQDiQV96TH7YLw2 content esgSubNav
In This List

Lupin launches fungal infection tablets, oral suspension in US

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Lupin launches fungal infection tablets, oral suspension in US

India's Lupin Ltd. announced the U.S. launch of Voriconazole to treat fungal infections in patients 12 years old and above.

The U.S.-FDA approved generic was launched in 50 mg and 200 mg tablets and 40 mg/ml oral suspension. Voriconazole will compete with PF Prism CV's Vfend tablets, which had U.S. sales of $81 million in the 12 months ended September and Vfend oral suspension which also generated $15.2 million during the same period.